Yarrow Bioscience Inc(YARW)

Biotechnology · New Haven, CT

$19.16-1.14 (-5.62%)

Delayed quote: Oct 6, 2026, 2:54 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:59:22.133Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:59:22.133Z.

Quote observation: 2026-10-06T18:54:08.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 178,271,557
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 22,925,000
TTM free cash flow · period ending 2026-06-30: -16,933,000

FMP input reference: a8ce9bd0ffb1cb5d8a686ad50c5c0fc76176a0385911c5cc34bdb5d73fbb2f35

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

YARW EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

YARW Competitors' EV/FCF Ratio

YARW

Yarrow Bioscience Inc

Current

Market Cap

$178.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs YARW

Market Cap

$181.30M

EV/FCF Ratio

N/A

TTM Avg

28.20x

3Y Avg

28.15x

5Y Avg

28.15x

CMPX

Compass Therapeutics, Inc.

vs YARW

Market Cap

$182.79M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs YARW

Market Cap

$183.55M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRQR

ProQR Therapeutics N.V.

vs YARW

Market Cap

$173.76M

EV/FCF Ratio

N/A

TTM Avg

3.88x

3Y Avg

3.88x

5Y Avg

3.88x

DERM

Journey Medical Corporation

vs YARW

Market Cap

$173.52M

EV/FCF Ratio

N/A

TTM Avg

72.04x

3Y Avg

55.57x

5Y Avg

55.57x

ANTX

AN2 Therapeutics, Inc.

vs YARW

Market Cap

$184.40M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DTIL

Precision BioSciences, Inc.

vs YARW

Market Cap

$171.26M

EV/FCF Ratio

N/A

TTM Avg

277.79x

3Y Avg

277.79x

5Y Avg

277.79x

CUE

Cue Biopharma, Inc.

vs YARW

Market Cap

$170.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORGO

Organogenesis Holdings Inc.

vs YARW

Market Cap

$169.85M

EV/FCF Ratio

9.15x

TTM Avg

14.67x

3Y Avg

65.56x

5Y Avg

51.74x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Yarrow Bioscience Inc (YARW)	$178.27M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$181.30M	N/A	28.20x	28.15x	28.15x
Compass Therapeutics, Inc. (CMPX)vs ›	$182.79M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$183.55M	N/A	N/A	N/A	N/A
ProQR Therapeutics N.V. (PRQR)vs ›	$173.76M	N/A	3.88x	3.88x	3.88x
Journey Medical Corporation (DERM)vs ›	$173.52M	N/A	72.04x	55.57x	55.57x
AN2 Therapeutics, Inc. (ANTX)vs ›	$184.40M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$171.26M	N/A	277.79x	277.79x	277.79x
Cue Biopharma, Inc. (CUE)vs ›	$170.21M	N/A	N/A	N/A	N/A
Organogenesis Holdings Inc. (ORGO)vs ›	$169.85M	9.15x	14.67x	65.56x	51.74x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

YARW EV/FCF Ratio Metrics

YARW Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics